newsfilter
← Latest News
PR Newswire·

Provention Bio Announces Positive Final Results from First-In-Human Study of Coxsackievirus B Vaccine Candidate PRV-101

PRV-101 continued to be well tolerated and elicited durable high titers of virus-neutralizing antibodies in a dose-dependent fashion in healthy volunteers RED BANK, N.J., March 28, 2022 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a biopharmaceu